CLDX
Celldex Therapeutics, Inc.26.68
-0.41-1.51%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.77BP/E (TTM)
-Basic EPS (TTM)
-3.38Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
EoE trial misses clinical mark
Celldex Therapeutics announced on August 19, 2025, that its Phase 2 study of barzolvolimab in eosinophilic esophagitis met the primary endpoint, achieving profound mast cell depletion in the esophagus with high statistical significance—peak counts dropped from 55.4 to 19.4 per high power field versus placebo's minor change. Yet clinical symptoms and endoscopic scores showed no improvement, proving mast cells aren't the main driver in EoE. The drug's safety profile held strong. Celldex halts EoE development but presses ahead with barzolvolimab in urticaria, dermatitis, and prurigo nodularis trials.
8-K
Q2 results and pipeline progress
Celldex Therapeutics reported Q2 2025 financials, highlighting strong Phase 2 data for barzolvolimab in chronic spontaneous urticaria, with up to 41% of patients achieving complete response seven months post-dosing and 48% reporting no quality-of-life impact. The company initiated a global Phase 3 program in CSU, targeting full enrollment next summer, while planning Phase 3 in chronic inducible urticaria for late 2025. Cash reserves stood at $630.3 million, funding operations through 2027. Data from additional barzolvolimab studies in EoE and CIndU, plus CDX-622 Phase 1, arrive in H2 2025.
10-Q
Q2 FY2025 results
Celldex Therapeutics posted a Q2 net loss of $56.6M, up 58% y/y from $35.8M, driven by R&D expenses climbing 37% to $54.2M amid barzolvolimab's Phase 3 push in chronic urticaria. Revenues dipped 71% y/y to $0.7M, mostly from waning Rockefeller contracts, while investment income fell 31% to $7.3M on lower balances. Yet cash and equivalents held at $23.0M, with total liquidity at $630.3M—enough for operations through 2027. Free cash flow isn't disclosed in the 10-Q. The Kolltan settlement lingers as a potential cash hit if barzolvolimab hits approval milestones. Clinical momentum builds steadily. Pipeline risks loom from trial delays.
ACLX
Arcellx, Inc.
66.33-2.01
ALDX
Aldeyra Therapeutics, Inc.
5.31+1.32
ANNX
Annexon, Inc.
4.80-0.11
CLLS
Cellectis S.A.
4.06-0.73
CLYM
Climb Bio, Inc.
4.62+0.81
CMPX
Compass Therapeutics, Inc.
5.24+0.16
CNTX
Context Therapeutics Inc.
1.10-0.03
XBIT
XBiotech Inc.
2.45-0.08
XTLB
XTL Biopharmaceuticals Ltd.
0.78-0.03
ZBIO
Zenas BioPharma, Inc.
36.89+4.30